Loading data for CLLS — first visit, this takes a few seconds.
Cellectis S.A. (CLLS)
NasdaqGM: CLLS
· 即時價格 · USD
3.32
+0.07 (2.15%)
收盤價： Sep 03, 2026, 8:00 PM
3.25
-2.11%
盤後: 7:30 PM
股價、關鍵數字和最新消息，都在這一頁。
Cellectis S.A.（CLLS）股價、分析與資料
無可用資料
| 買價 | 2.8 |
| 市值 | 334M |
| 營收 (ttm) | 63.8M |
| 淨利（ttm） | -65.3M |
| 2.75 | |
| -0.64 | |
| n/a | |
| -5.35 | |
| P/B (ttm) | 5.88 |
| P/S (ttm) | 5.24 |
| 財報日期 | Nov 13, 2026 |
| 賣價 | 2.99 |
| 成交量 | 20,597 |
| 20 日平均成交量 | 25,441 |
| 開盤價 | 3.39 |
| 前收盤價 | 3.25 |
| 當日區間 | 3.26 - 3.44 |
| 52 週範圍 | 2.35 - 5.48 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 CLLS
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, design...
完整的公司簡介財報驚奇
Cellectis S.A. 已於 Aug 6, 2026 公布季度財報：
- 營收為 $5.23M 低於預期 $0, 年增 -68.74% 下滑.
- 每股盈餘為 -0.22 超出預期 0.03, 年增 0.00% 成長.
第 1 頁，共 2 頁